Unlocking the Value of Biosimilar Therapies in IBD
Premiere Date: Thursday, February 4, 2021This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- ABIM (MOC)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, February 4, 2022
Note: Credit Is No Longer Available
 | Miguel Regueiro, MD, AGAF, FACG, FACP Chair, Digestive Disease and Surgery Chair, Department of Gastroenterology, Hepatology, and Nutrition The Pier C. and Renee A. Borra Family Endowed Chair in Gastroenterology and Hepatology Professor, Department of Medicine Cleveland Clinic Lerner College of Medicine of Case Western Reserve University Cleveland, OH |
 | Christina Ha, MD, FACG, AGAF Inflammatory Bowel Disease Center Mayo Clinic Scottsdale, AZ |
Over the years, biologic agents have proven their importance in the management of chronic autoimmune diseases including inflammatory bowel disease (IBD). Biosimilars are molecules highly similar to approved biologic medicines that have been developed to mitigate the high costs of biologics. Despite the fact that these therapies are tested to ensure non-inferiority to originator products, questions about appropriate use of biosiilars in IBD remain among clinicians and patients alike.
In this CME Outfitters webcast, expert faculty will focus on identifying key terminology related to biosimilar products, assessing evidence regarding the efficacy and safety of biosimilars in IBD, and improving patient-provider communication patterns on the topic of biosimilars.
At the end of this CE activity, participants should be able to:
- Identify the key terminology related to biosimilar products such as interchangeability, substitution, and switching.
- Assess clinical trial and real-world evidence of efficacy and safety of biosimilars in IBD.
- Improve patient-provider communication patterns regarding appropriate use of biosimilars.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Identify the key terminology related to biosimilar products such as interchangeability, substitution, and switching.
- Assess clinical trial and real-world evidence of efficacy and safety of biosimilars in IBD.
- Explain how to improve patient-provider communication patterns regarding appropriate use of biosimilars.
This activity is supported by educational funding provided by Amgen
Gastroenterologists, PAs, nurse practitioners, nurses, pharmacists
CME Credit (Physicians):
The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The AGA Institute designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs). Universal Activity Number:
Enduring: JA0007185-0000-21-109-H01-P
Type: knowledge-based
ABIM/MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Learning Format:
Enduring material
Royal College MOC Credit:
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME's "CME in Support of MOC" program in Section 3 of the Royal College's MOC Program.
Note to PAs: PAs may claim a maximum of 1.5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy.
Disclosure Declaration
It is the policy of AGA and CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Regueiro reports that he receives research support from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He receives unrestricted educational grants from AbbVie Inc.; Janssen Pharmaceuticals, Inc.; Salix Pharmaceuticals; Shire; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc. He is on the advisory board or a consultant for AbbVie Inc.; Amgen Inc.; Celgene Corporation; Janssen Pharmaceuticals, Inc.; Miraca Laboratories; Pfizer Inc.; Seres Therapeutics; Takeda Pharmaceuticals U.S.A., Inc.; and UCB, Inc.
Dr. Ha reports that she receives grant support from Pfizer Inc. She receives research support from Eli Lilly and Company and Pfizer Inc. She is on the advisory board for AbbVie Inc.; Eli Lilly and Company; Ferring Pharmaceuticals; Genentech, Inc.; InDex Pharmaceuticals; Janssen Pharmaceuticals, Inc; Pfizer Inc.; Salix Pharmaceuticals; and Takeda Pharmaceuticals U.S.A., Inc.
Howard Bliwise, MD (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Olga Askinazi, PhD (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Susan Perry (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Disclosures were obtained from the American Gastroenterological Association staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
MMV-111-020421-26
